Ottawa and Vancouver, Canada (June 7, 2016) – Zymeworks Inc., a leader in the development of bi-specific and multi-specific antibodies, announced today that it was honored as the Biotech Company of the Year by BIOTECanada at this year’s BIO International …
Trending at Lumira Ventures
The Top 5 Canadian Biotech CEOs who elevate their companies
BY COMPILED BY SHAWN LAWRENCE • MARCH 11, 2016 • BUSINESS FOCUS, FEATURE SLIDER, FEATURED-SLIDES-HOME, MANAGEMENT UPDATES • COMMENTS (0) • 798 The-Top-5-Canadian-Biotech-CEOs-They are industry leaders that capture the attention and confidence of the Canadian biotech investment community. They represent …
Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. today announced the successful achievement of a research milestone in its collaboration with Eli Lilly and Company in the development of a novel immune-modulating bi-specific antibody using Zymeworks’ proprietary Azymetric™ platform. In accordance with the …
Zymeworks and Kairos Therapeutics Enter into Strategic Partnership and Optional Merger Agreement to Develop Antibody Drug Conjugates and Bi-Specific Antibodies
Vancouver, Canada – January 8, 2016: Zymeworks Inc. and Kairos Therapeutics Inc., both privately-held biotech companies headquartered in Vancouver, today announced they have entered into a strategic partnership whereby Zymeworks, a leader in the development of bi-specific and multi-specific antibodies, …
Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics
Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics January 08, 2016 Vancouver, Canada – Zymeworks Inc. today announced the closing of a US$ 61.5 million Series A …